| Literature DB >> 30868114 |
Lisa Ouss1,2, Dorothee Leunen1,2, Jacques Laschet1, Nicole Chemaly1, Giulia Barcia3, Emma M Losito1, Aveline Aouidad4, Zoe Barrault1, Isabelle Desguerre1, Delphine Breuillard1, Rima Nabbout1.
Abstract
OBJECTIVE: We aimed to assess a cohort of young patients with Dravet syndrome (DS) for intellectual disability (ID) and autism spectrum disorder (ASD) using standardized tools and parental questionnaires to delineate their specific profiles.Entities:
Keywords: Parents’ questionnaires; autism spectrum disorder; cognitive scales; epileptic encephalopathy; intellectual disability
Year: 2018 PMID: 30868114 PMCID: PMC6398110 DOI: 10.1002/epi4.12281
Source DB: PubMed Journal: Epilepsia Open ISSN: 2470-9239
Description of “autistic features” in patients with Dravet syndrome (DS) in the literature
| No. patients | Age (y) | Assessment instruments | % ASD | Autistic traits % | Social problems % | Communication/language disorders | No play with toys % | Restricted interests RI, Repetitive behavior % | Hyperactivity, attention problems % | Other | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nabbout et al. (2009) | 28 | 11 (4‐24) | Clinical evaluation | NA | 46.4 | NA | No language 53.6, few words 32.1, short sentences 14.3 | NA | NA | 22.2 | NA |
| Ragona et al. (2011) | 26 | 5‐19 | Clinical evaluation | NA | 15.4 | NA | NA | NA | NA | 83.3; 69.2 | NA |
| Dravet et al. (2011) | NA | NA | Clinical evaluation | NA | NA | No play with peers | Language delay | Yes | NA | Attention | NA |
| Ceulemans et al. (2011) | 60/24 | NA | Vineland | 8.3 | NA | NA | NA | NA | NA | Yes | NA |
| Genton et al. (2011) | 24 | 20‐50 | Clinical evaluation | 25 | NA | NA | Language impairment 100 | NA | NA | NA | NA |
| Chieffo et al. (2011) | 12 | Survey 2‐6 y | Griffith's dev. scale | 8.3 | NA | NA | NA | NA | NA | NA | NA |
| Brunklaus et al. (2011) | 163 | 7.2 | SDQ, PedsQL | NA | NA | Peer relationship 75 | NA | NA | NA | Attention 66 | Conduct problem 33 |
| Skluzacek et al. (2011) (2005 cohort) | 65 | 7.7 (<1‐36) | Clinical evaluation | 18 | 40 | Withdrawn 18 | Echolalia 18, no language 48, language delay 68 | 14 | Self‐stimulation 26, perseveration 35, obsessions 24 | 20 | Excessive familiarity 47 |
| Skluzacek (2011) (2009 cohort) | 86 | 7.7 (<1‐36) | Clinical evaluation | 21 | 33 | 10 | Echolalia 24, no language 28, language delay 83 | 30 | Self‐stimulation 20, perseveration 52, obsessions 40 | 34 | Excessive familiarity 56 |
| Li et al. (2011) | 37 | 9.3 (2.8‐12.3) | DSM‐IV‐TR, ICD‐10, ABC, CARS | 24.3 | 97.3 at least one feature | Emotional reciprocity 27 | Speech delay 91.9: language regression 10.8 | NA | Adherence to routine 32.4, restricted interests 55 | NA | 54.1 short temper |
| Villeneuve et al. (2013) | 21 | 6‐20 | Vineland | NA | 100 at least one feature | Gaze, friendships, social rules | 91% verbal IQ < 60 | NA | Unusual + restricted interests | Opposition/provocation | Excessive familiarity |
| Berkvens et al. (2015) | 13 | 34.7 (18‐60) | AVZ‐R, SGZ, TVZ | 61.5 | NA | 69.2 | 84.6 | 69.2 | Stereotyped use, adherence to routine 46.1; restricted interests 69.2 | None | Self‐mutilation |
| Rosander et al. (2015) | 42 | 7 (1‐17) | Play observations, parental interview | 36 | 16 | 7 | NA | NA | NA | NA | NA |
| Villas et al. (2017) | 220 | 8 (0.9‐32) | Parental survey | NA | 67 | 53 | Language delay 84 | 49 | 68 | 50 | Excessive familiarity 57 |
ABC, Autism Behavior Checklist; AVZ‐R, Pervasive Developmental Disorder in Mental Retardation scale‐Revised; CARS, Childhood Autism Rating Scale; DSM‐IV‐TR, Diagnostic and Statistical Manual of Mental Disorders Revised, Fourth Edition; ICD‐10, International Classification of Diseases, Tenth Revision; NA, not available; PedsQL, Pediatric Quality of Life Inventory; SDQ, Strength and Difficulties Questionnaire; SGZ, Maladaptive behavior scale for individuals with ID; TVZ, Temperament scale for individuals with ID.
Genetic, seizure, and neurodevelopmental assessment data
| No. | Age at inclusion (mo) | Gender | Mutation | Exon/intron | De novo/heredity | Age at onset of seizure (mo) | Trigger | Seizures semiology | Status epilepticus at onset | Age at treatment introduction (mo) | Treatment | Autism | Delay (CDI) | Delay (PEP‐3) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 84 | M | Negative | NA | NA | 8 | Fever | F | N | 8 | VPA, STP, CLB | No | ++ | ++ |
| 2 | 33 | M | c1165C3T | Exon 8 | NA | 5 | Fever/Vac | GTC | Y | 6 | VPA, CLB, TPM, STP | No | NA | ++ |
| 3 | 87 | M | c.580G>A/p.Asp194Asn | Exon 4 | De novo | 9 | Fever | GTC | N | NA | VPA, CLB, STP | No | ++ | ++ |
| 4 | 64 | F | c.4219C>T/p.Arg1407X | Exon 21 | NA | 9 | Fever | TC right | Y | 12 | VPA, TPM | ASD | ++ | ++ |
| 5 | 65 | M | p.lys868Asn C.2604G>C | Exon 15 | Mother | 6 | Fever | GTC | N | 8 | VPA, CLB, TPM | No/SCD | ++ | + |
| 6 | 91 | M | c.473+1G>A | Intron 3 | De novo | 4 | Fever | GTC | Y | 4 | VPA | No | ++ | ++ |
| 7 | 50 | M | c.2360T>G/p.Met787Arg | Exon 13 | De novo | 9 | Fever/Vac | F | Y | 13 | VPA, CLB, STP | ASD | + | + |
| 8 | 45 | F | c.2836C>T/p.Arg946Cys | Exon 15 | De novo | 6 | Fever | GTC | N | 8 | VPA, CLB, STP | No | ++ | ++ |
| 9 | 71 | F | Negative | NA | NA | 6 | Fever | Atonic, GTC | N | 7 | TPM, VPA, CLB, CZP | ASD | ++ | ++ |
| 10 | 35 | F | c.4476+1_4476+5del | Intron 23 | De novo | 6 | Fever | GTC | N | 6 | VPA, CLB, STP | No | ++ | ++ |
| 11 | 62 | M | Negative | NA | NA | 13 | Fever | GTC | N | 20 | VPA, TPM, STP | No | ++ | ++ |
| 12 | 58 | F | Negative | NA | NA | 10 | Fever | F, GTC, pattern sensitivity myoclonia | N | 16 | VPA, LEV, CLB | NA | ++ | + |
| 13 | 35 | F | c.568T>C/p.Trp190Arg | Exon 4 | De novo | 7 | Fever | F | Y | 10 | VPA, CLB | No | + | − |
| 14 | 26 | M | c.5734C>T p.(Arg1912*) | Exon 26 | De novo | 2 | Vac | GTC | N | 4 | VPA | No | ++ | + |
| 15 | 77 | F | c.1378C>T/p.GIn460 | Exon 10 | De novo | 10 | No | GTC | N | 10 | VPA | No | ++ | ++ |
| 16 | 64 | F | Negative | NA | NA | 5 | No | C | Y | 13 | VPA, CLB, STP | NO/SCD | ++ | ++ |
| 17 | 57 | M | c.2951T>G/p.Leu984Arg exon 16; (c.4339‐34_4339‐30delTggta intron 22 variant) | Exon 16 | De novo | 6 | Fever | GC | N | 6 | VPA, CLB, STP | ASD | NA | ++ |
| 18 | 90 | M | c.5040delC/p.Met1681CysfsX1714 | Exon 26 | De novo | 4 | Fever | Hemicorporal | N | 10 | VPA, CLB, STP | ASD | ++ | ++ |
| 19 | 57 | F | NA | NA | NA | 3 | No | GTC | Y | 3.5 | Br, VPA, CLB, STP | No | NA | ++ |
| 20 | 91 | M | c.2792G>A/p.Arg931His | Exon 15 | De novo | 5 | Fever | GTC | Y | 5 | VPA, CLB, STP | ASD | ++ | ++ |
| 21 | 78 | F | c.5209A>T (p.Lys1737*) | Exon 26 | De novo | 7 | Fever | GTC | Y | 8 | VPA, STP, CLB | ASD | ++ | ++ |
| 22 | 46 | M | c.1129C>T/p.Arg377X | NA | 6 | Fever | GTC | Y | 8 | VPA, CLB | NA | − | + | |
| 23 | 40 | F | c.3213del (p.Asp1072llefs*8) | Exon 16 | De novo | 7 | Fever | Right hemiclonic | Y | 8 | LEV, VPA, CLB, TPM | No | + | + |
| 24 | 78 | F | c.4757delG/p.Gly1586GlufsX5 | Exon 25 | NA | 3 | Fever | GTC | N | 6 | VPA, CLB, STP | ASD | ++ | ++ |
| 25 | 47 | F | c.1849A>T/p.Arg617X | Exon 11 | De novo | 6 | No | F | N | 10 | VPA, STP, CLB | No | + | ++ |
| 26 | 70 | F | c.455C>T/p.Pro1519Ser | Exon 24 | Mother | 9 | No | GTC | Y | 10 | VPA, CLB | ASD | ++ | ++ |
| 27 | 77 | F | c.235G>T.Asp 79Tyr | Exon 1 | Mosaicism mother | 8 | Fever | GTC | N | NA | CLB, VPA, STP | ASD | NA | ++ |
| 28 | 69 | M | c.974A>G/p.Tyr325Cys | NA | NA | 7 | Fever | GTC | Y | 7 | VPA | No | ++ | ++ |
| 29 | 67 | F | Negative | NA | NA | 7 | Fever | T | NA | NA | VPA, STP, CLB | ASD | ++ | ++ |
| 30 | 81 | F | c.602+1G>A i | Intron 4 | De novo | 9 | Fever | GTC | Y | 12 | VPA, STP, CLB | No | ++ | ++ |
ASD, Autism Spectrum Disorder; BR, potassium bromide; C, clonic seizures; CLB, clobazam; CZP, clonazepam; FS, focal seizures; GC, generalized clonic seizures; GTC, generalized tonic‐clonic seizures; LEV, levetiracetam; M, myoclonic; NA, not available; SCD, Social Communication Disorder; STP, stiripentol; TC, tonic‐clonic seizures; TPM, topiramate; Vac, vaccination; VPA, sodium valproate; (−), no risk of delay; (+) = high level risk of delay, DQ <85; (++) very high risk of delay, QD <70 (categorization of delay were obtained with mean PEP‐3 cognitive DQ).
Figure 1Upper graph—proportion of patients for each developmental level of PEP‐3 scale according to the subscales. CVPV, Cognitive Verbal/Preverbal; EL, Expressive Language; RL, Receptive Language; FM, Fine Motor; GM, Gross Motor; VMI, Visual Motor Imitation; AE, Affective Expression; SR, Social Reciprocity; CMB, Characteristic Motor Behaviors; CVB, Characteristic Verbal Behaviors. Lower graph: Proportion of patients for each developmental level of the CDI scale according to the subscales. Soc, Social; SH, Self Help; GM, Gross Motor; FM, Fine Motor; EL, Expressive Language; LC, Language Comprehension; Let, Letters; Num, Numbers; GS, General Scale
Figure 2Nonparametric density plot of bivariate analyses of the variables “PEP‐3 Receptive Language” and “CDI General Scale” with respect to Age (M = months)
Figure 3Flow chart for diagnosis of autism spectrum disorder
Figure 4Comparison of ADI‐R 3 subscores between Dravet syndrome (DS) children with autism spectrum disorder (ASD; in red) and DS children without ASD (in blue)